Main Menu

Publications Highlights View all by category

Types of Publications


Journal Articles

Telli, M.L. Tolaney, S.M. Shapiro, G.I. Middleton, M. Lord, S.R. Arkenau, H.T. Tutt, A. Abramson, V. Dean, E. Haddad, T.C. Wesolowski, R. Ferrer-Playan, J. Goddemeier, T. Grombacher, T. Dong, J. Fleuranceau-Morel, P. Diaz-Padilla, I. Plummer, R. (2022). Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. Npj breast cancer, Vol.8 (1), pp. 45-?.  show abstract

Rätze, M.A. Koorman, T. Sijnesael, T. Bassey-Archibong, B. van de Ven, R. Enserink, L. Visser, D. Jaksani, S. Viciano, I. Bakker, E.R. Richard, F. Tutt, A. O'Leary, L. Fitzpatrick, A. Roca-Cusachs, P. van Diest, P.J. Desmedt, C. Daniel, J.M. Isacke, C.M. Derksen, P.W. (2022). Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer. Oncogene, .  show abstract

Sipos, O. Tovey, H. Quist, J. Haider, S. Nowinski, S. Gazinska, P. Kernaghan, S. Toms, C. Maguire, S. Orr, N. Linn, S.C. Owen, J. Gillett, C. Pinder, S.E. Bliss, J.M. Tutt, A. Cheang, M.C. Grigoriadis, A. (2021). Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial. Annals of oncology : official journal of the european society for medical oncology, Vol.32 (1), pp. 58-65.  show abstract

Tutt, A.N. Garber, J.E. Kaufman, B. Viale, G. Fumagalli, D. Rastogi, P. Gelber, R.D. de Azambuja, E. Fielding, A. Balmaña, J. Domchek, S.M. Gelmon, K.A. Hollingsworth, S.J. Korde, L.A. Linderholm, B. Bandos, H. Senkus, E. Suga, J.M. Shao, Z. Pippas, A.W. Nowecki, Z. Huzarski, T. Ganz, P.A. Lucas, P.C. Baker, N. Loibl, S. McConnell, R. Piccart, M. Schmutzler, R. Steger, G.G. Costantino, J.P. Arahmani, A. Wolmark, N. McFadden, E. Karantza, V. Lakhani, S.R. Yothers, G. Campbell, C. Geyer, C.E. OlympiA Clinical Trial Steering Committee and Investigators, (2021). Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. The new england journal of medicine, Vol.384 (25), pp. 2394-2405.  show abstract

Stevenson, J. Barrow-McGee, R. Yu, L. Paul, A. Mansfield, D. Owen, J. Woodman, N. Natrajan, R. Haider, S. Gillett, C. Tutt, A. Pinder, S.E. Choudary, J. Naidoo, K. (2021). Proteomics of REPLICANT perfusate detects changes in the metastatic lymph node microenvironment. Npj breast cancer, Vol.7 (1), pp. 24-?.  show abstract

Bajrami, I. Walker, C. Krastev, D.B. Weekes, D. Song, F. Wicks, A.J. Alexander, J. Haider, S. Brough, R. Pettitt, S.J. Tutt, A.N. Lord, C.J. (2021). Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency. Commun biol, Vol.4 (1), pp. 1270-?.  show abstract

Harris, R.J. Cheung, A. Ng, J.C. Laddach, R. Chenoweth, A.M. Crescioli, S. Fittall, M. Dominguez Rodriguez, D. Roberts, J. Levi, D. Liu, F. Alberts, E. Quist, J. Santaolalla, A. Pinder, S.E. Gillett, C. Hammar, N. Irshad, S. Van Hemelrijck, M. Dunn-Walters, D.K. Fraternali, F. Spicer, J.F. Lacy, K.E. Tsoka, S. Grigoriadis, A. Tutt, A.N. Karagiannis, S.N. (2021). Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes In Triple-Negative Breast Cancer. Cancer research, .  show abstract

Zatreanu, D. Robinson, H.M. Alkhatib, O. Boursier, M. Finch, H. Geo, L. Grande, D. Grinkevich, V. Heald, R.A. Langdon, S. Majithiya, J. McWhirter, C. Martin, N.M. Moore, S. Neves, J. Rajendra, E. Ranzani, M. Schaedler, T. Stockley, M. Wiggins, K. Brough, R. Sridhar, S. Gulati, A. Shao, N. Badder, L.M. Novo, D. Knight, E.G. Marlow, R. Haider, S. Callen, E. Hewitt, G. Schimmel, J. Prevo, R. Alli, C. Ferdinand, A. Bell, C. Blencowe, P. Bot, C. Calder, M. Charles, M. Curry, J. Ekwuru, T. Ewings, K. Krajewski, W. MacDonald, E. McCarron, H. Pang, L. Pedder, C. Rigoreau, L. Swarbrick, M. Wheatley, E. Willis, S. Wong, A.C. Nussenzweig, A. Tijsterman, M. Tutt, A. Boulton, S.J. Higgins, G.S. Pettitt, S.J. Smith, G.C. Lord, C.J. (2021). Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Nature communications, Vol.12 (1), pp. 3636-?.  show abstract

Fitzpatrick, A. Iravani, M. Mills, A. Childs, L. Alaguthurai, T. Clifford, A. Garcia-Murillas, I. Van Laere, S. Dirix, L. Harries, M. Okines, A. Turner, N.C. Haider, S. Tutt, A.N. Isacke, C.M. (2021). Assessing CSF ctDNA to improve diagnostic accuracy and therapeutic monitoring in breast cancer leptomeningeal metastasis. Clinical cancer research : an official journal of the american association for cancer research, .  show abstract

Peck, B. Bland, P. Mavrommati, I. Muirhead, G. Cottom, H. Wai, P.T. Maguire, S.L. Barker, H.E. Morrison, E. Kriplani, D. Yu, L. Gibson, A. Falgari, G. Brennan, K. Farnie, G. Buus, R. Marlow, R. Novo, D. Knight, E. Guppy, N. Kolarevic, D. Susnjar, S. Milijic, N.M. Naidoo, K. Gazinska, P. Roxanis, I. Pancholi, S. Martin, L.-. Holgersen, E.M. Cheang, M.C. Noor, F. Postel-Vinay, S. Quinn, G. McDade, S. Krasny, L. Huang, P. Daley, F. Wallberg, F. Choudhary, J.S. Haider, S. Tutt, A.N. Natrajan, R. (2021). 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. Cancer research, .  show abstract

Kos, Z. Roblin, E. Kim, R.S. Michiels, S. Gallas, B.D. Chen, W. van de Vijver, K.K. Goel, S. Adams, S. Demaria, S. Viale, G. Nielsen, T.O. Badve, S.S. Symmans, W.F. Sotiriou, C. Rimm, D.L. Hewitt, S. Denkert, C. Loibl, S. Luen, S.J. Bartlett, J.M. Savas, P. Pruneri, G. Dillon, D.A. Cheang, M.C. Tutt, A. Hall, J.A. Kok, M. Horlings, H.M. Madabhushi, A. van der Laak, J. Ciompi, F. Laenkholm, A.-. Bellolio, E. Gruosso, T. Fox, S.B. Araya, J.C. Floris, G. Hudeček, J. Voorwerk, L. Beck, A.H. Kerner, J. Larsimont, D. Declercq, S. Van den Eynden, G. Pusztai, L. Ehinger, A. Yang, W. AbdulJabbar, K. Yuan, Y. Singh, R. Hiley, C. Bakir, M.A. Lazar, A.J. Naber, S. Wienert, S. Castillo, M. Curigliano, G. Dieci, M.-. André, F. Swanton, C. Reis-Filho, J. Sparano, J. Balslev, E. Chen, I.-. Stovgaard, E.I. Pogue-Geile, K. Blenman, K.R. Penault-Llorca, F. Schnitt, S. Lakhani, S.R. Vincent-Salomon, A. Rojo, F. Braybrooke, J.P. Hanna, M.G. Soler-Monsó, M.T. Bethmann, D. Castaneda, C.A. Willard-Gallo, K. Sharma, A. Lien, H.-. Fineberg, S. Thagaard, J. Comerma, L. Gonzalez-Ericsson, P. Brogi, E. Loi, S. Saltz, J. Klaushen, F. Cooper, L. Amgad, M. Moore, D.A. Salgado, R. International Immuno-Oncology Biomarker Working Group, (2020). Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj breast cancer, Vol.6, pp. 17-?.  show abstract

Barrow-McGee, R. Procter, J. Owen, J. Woodman, N. Lombardelli, C. Kothari, A. Kovacs, T. Douek, M. George, S. Barry, P.A. Ramsey, K. Gibson, A. Buus, R. Holgersen, E. Natrajan, R. Haider, S. Shattock, M.J. Gillett, C. Tutt, A.N. Pinder, S.E. Naidoo, K. (2020). Real-time ex vivo perfusion of human lymph nodes invaded by cancer (REPLICANT): a feasibility study. The journal of pathology, Vol.250 (3), pp. 262-274.  show abstract

ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, (2020). Pan-cancer analysis of whole genomes. Nature, Vol.578 (7793), pp. 82-93.  show abstract

Yeow, Z.Y. Lambrus, B.G. Marlow, R. Zhan, K.H. Durin, M.-. Evans, L.T. Scott, P.M. Phan, T. Park, E. Ruiz, L.A. Moralli, D. Knight, E.G. Badder, L.M. Novo, D. Haider, S. Green, C.M. Tutt, A.N. Lord, C.J. Chapman, J.R. Holland, A.J. (2020). Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer. Nature, Vol.585 (7825), pp. 447-452.  show abstract

Pettitt, S.J. Frankum, J.R. Punta, M. Lise, S. Alexander, J. Chen, Y. Yap, T.A. Haider, S. Tutt, A.N. Lord, C.J. (2020). Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance. Cancer discovery, Vol.10 (10), pp. 1475-1488.  show abstract

Chopra, N. Tovey, H. Pearson, A. Cutts, R. Toms, C. Proszek, P. Hubank, M. Dowsett, M. Dodson, A. Daley, F. Kriplani, D. Gevensleben, H. Davies, H.R. Degasperi, A. Roylance, R. Chan, S. Tutt, A. Skene, A. Evans, A. Bliss, J.M. Nik-Zainal, S. Turner, N.C. (2020). Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nature communications, Vol.11 (1), pp. 2662-?.  show abstract

Fitzpatrick, A. Tutt, A. (2019). Controversial issues in the neoadjuvant treatment of triple-negative breast cancer. Therapeutic advances in medical oncology, Vol.11, pp. 1758835919882581-?.  show abstract

Quist, J. Mirza, H. Cheang, M.C. Telli, M.L. O'Shaughnessy, J.A. Lord, C.J. Tutt, A.N. Grigoriadis, A. (2019). A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics. Molecular cancer therapeutics, Vol.18 (1), pp. 204-212.  show abstract

Chabanon, R.M. Muirhead, G. Krastev, D.B. Adam, J. Morel, D. Garrido, M. Lamb, A. Hénon, C. Dorvault, N. Rouanne, M. Marlow, R. Bajrami, I. Cardeñosa, M.L. Konde, A. Besse, B. Ashworth, A. Pettitt, S.J. Haider, S. Marabelle, A. Tutt, A.N. Soria, J.-. Lord, C.J. Postel-Vinay, S. (2019). PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. The journal of clinical investigation, Vol.129 (3), pp. 1211-1228.  show abstract

Evans, R. Flores-Borja, F. Nassiri, S. Miranda, E. Lawler, K. Grigoriadis, A. Monypenny, J. Gillet, C. Owen, J. Gordon, P. Male, V. Cheung, A. Noor, F. Barber, P. Marlow, R. Francesch-Domenech, E. Fruhwirth, G. Squadrito, M. Vojnovic, B. Tutt, A. Festy, F. De Palma, M. Ng, T. (2019). Integrin-Mediated Macrophage Adhesion Promotes Lymphovascular Dissemination in Breast Cancer. Cell reports, Vol.27 (7), pp. 1967-1978.e4.  show abstract

Wu, Y. Kyle-Cezar, F. Woolf, R.T. Naceur-Lombardelli, C. Owen, J. Biswas, D. Lorenc, A. Vantourout, P. Gazinska, P. Grigoriadis, A. Tutt, A. Hayday, A. (2019). An innate-like Vδ1 + γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer. Science translational medicine, Vol.11 (513).  show abstract

Mateo, J. Lord, C.J. Serra, V. Tutt, A. Balmaña, J. Castroviejo-Bermejo, M. Cruz, C. Oaknin, A. Kaye, S.B. de Bono, J.S. (2019). A decade of clinical development of PARP inhibitors in perspective. Annals of oncology : official journal of the european society for medical oncology, Vol.30 (9), pp. 1437-1447.  show abstract

Naidoo, K. Wai, P.T. Maguire, S.L. Daley, F. Haider, S. Kriplani, D. Campbell, J. Mirza, H. Grigoriadis, A. Tutt, A. Moseley, P.M. Abdel-Fatah, T.M. Chan, S.Y. Madhusudan, S. Rhaka, E.A. Ellis, I.O. Lord, C.J. Yuan, Y. Green, A.R. Natrajan, R. (2018). Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer. Molecular cancer therapeutics, Vol.17 (1), pp. 306-315.  show abstract

Tutt, A. (2018). Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness. Ann oncol, Vol.29 (1), pp. 18-21.

Rodrigues, N.V. Correia, D.V. Mensurado, S. Nóbrega-Pereira, S. deBarros, A. Kyle-Cezar, F. Tutt, A. Hayday, A.C. Norell, H. Silva-Santos, B. Dias, S. (2018). Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells. Cancer immunology research, Vol.6 (4), pp. 448-457.  show abstract

Muliaditan, T. Opzoomer, J.W. Caron, J. Okesola, M. Kosti, P. Lall, S. Van Hemelrijck, M. Dazzi, F. Tutt, A. Grigoriadis, A. Gillett, C.E. Madden, S.F. Burchell, J.M. Kordasti, S. Diebold, S.S. Spicer, J.F. Arnold, J.N. (2018). Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer. Clinical cancer research, Vol.24 (7), pp. 1617-1628.

Natrajan, R. Tutt, A.N. Lord, C.J. (2018). Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast Cancer. Cancer discovery, Vol.8 (3), pp. 272-275.  show abstract

Bajrami, I. Marlow, R. van de Ven, M. Brough, R. Pemberton, H.N. Frankum, J. Song, F. Rafiq, R. Konde, A. Krastev, D.B. Menon, M. Campbell, J. Gulati, A. Kumar, R. Pettitt, S.J. Gurden, M.D. Cardenosa, M.L. Chong, I. Gazinska, P. Wallberg, F. Sawyer, E.J. Martin, L.-. Dowsett, M. Linardopoulos, S. Natrajan, R. Ryan, C.J. Derksen, P.W. Jonkers, J. Tutt, A.N. Ashworth, A. Lord, C.J. (2018). E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. Cancer discovery, Vol.8 (4), pp. 498-515.  show abstract

Tutt, A. Tovey, H. Cheang, M.C. Kernaghan, S. Kilburn, L. Gazinska, P. Owen, J. Abraham, J. Barrett, S. Barrett-Lee, P. Brown, R. Chan, S. Dowsett, M. Flanagan, J.M. Fox, L. Grigoriadis, A. Gutin, A. Harper-Wynne, C. Hatton, M.Q. Hoadley, K.A. Parikh, J. Parker, P. Perou, C.M. Roylance, R. Shah, V. Shaw, A. Smith, I.E. Timms, K.M. Wardley, A.M. Wilson, G. Gillett, C. Lanchbury, J.S. Ashworth, A. Rahman, N. Harries, M. Ellis, P. Pinder, S.E. Bliss, J.M. (2018). Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine, Vol.24 (5), pp. 628-637.  show abstract

Grigoriadis, A. Gazinska, P. Pai, T. Irhsad, S. Wu, Y. Millis, R. Naidoo, K. Owen, J. Gillett, C.E. Tutt, A. Coolen, A.C. Pinder, S.E. (2018). Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node-positive breast cancers. The journal of pathology. clinical research, Vol.4 (1), pp. 39-54.  show abstract

Patel, N. Weekes, D. Drosopoulos, K. Gazinska, P. Noel, E. Rashid, M. Mirza, H. Quist, J. Brasó-Maristany, F. Mathew, S. Ferro, R. Pereira, A.M. Prince, C. Noor, F. Francesch-Domenech, E. Marlow, R. de Rinaldis, E. Grigoriadis, A. Linardopoulos, S. Marra, P. Tutt, A.N. (2018). Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer. Nature communications, Vol.9 (1), pp. 1044-?.  show abstract

Irshad, S. Flores-Borja, F. Lawler, K. Monypenny, J. Evans, R. Male, V. Gordon, P. Cheung, A. Gazinska, P. Noor, F. Wong, F. Grigoriadis, A. Fruhwirth, G.O. Barber, P.R. Woodman, N. Patel, D. Rodriguez-Justo, M. Owen, J. Martin, S.G. Pinder, S.E. Gillett, C.E. Poland, S.P. Ameer-Beg, S. McCaughan, F. Carlin, L.M. Hasan, U. Withers, D.R. Lane, P. Vojnovic, B. Quezada, S.A. Ellis, P. Tutt, A.N. Ng, T. (2017). RORγt + Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers. Cancer research, Vol.77 (5), pp. 1083-1096.

Davies, H. Glodzik, D. Morganella, S. Yates, L.R. Staaf, J. Zou, X. Ramakrishna, M. Martin, S. Boyault, S. Sieuwerts, A.M. Simpson, P.T. King, T.A. Raine, K. Eyfjord, J.E. Kong, G. Borg, Å. Birney, E. Stunnenberg, H.G. van de Vijver, M.J. Børresen-Dale, A.-. Martens, J.W. Span, P.N. Lakhani, S.R. Vincent-Salomon, A. Sotiriou, C. Tutt, A. Thompson, A.M. Van Laere, S. Richardson, A.L. Viari, A. Campbell, P.J. Stratton, M.R. Nik-Zainal, S. (2017). HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nature medicine, Vol.23 (4), pp. 517-525.  show abstract

Gracio, F. Burford, B. Gazinska, P. Mera, A. Mohd Noor, A. Marra, P. Gillett, C. Grigoriadis, A. Pinder, S. Tutt, A. de Rinaldis, E. (2017). Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patients' survival. Scientific reports, Vol.7, pp. 40177-?.  show abstract

Denkert, C. Liedtke, C. Tutt, A. von Minckwitz, G. (2017). Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet (london, england), Vol.389 (10087), pp. 2430-2442.  show abstract

Coles, C.E. Griffin, C.L. Kirby, A.M. Titley, J. Agrawal, R.K. Alhasso, A. Bhattacharya, I.S. Brunt, A.M. Ciurlionis, L. Chan, C. Donovan, E.M. Emson, M.A. Harnett, A.N. Haviland, J.S. Hopwood, P. Jefford, M.L. Kaggwa, R. Sawyer, E.J. Syndikus, I. Tsang, Y.M. Wheatley, D.A. Wilcox, M. Yarnold, J.R. Bliss, J.M. IMPORT Trialists, (2017). Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet (london, england), Vol.390 (10099), pp. 1048-1060.  show abstract

Koo, C.-. Giacomini, C. Reyes-Corral, M. Olmos, Y. Tavares, I.A. Marson, C.M. Linardopoulos, S. Tutt, A.N. Morris, J.D. (2017). Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells. Molecular cancer therapeutics, Vol.16 (11), pp. 2410-2421.  show abstract

Lawler, K. Papouli, E. Naceur-Lombardelli, C. Mera, A. Ougham, K. Tutt, A. Kimbung, S. Hedenfalk, I. Zhan, J. Zhang, H. Buus, R. Dowsett, M. Ng, T. Pinder, S.E. Parker, P. Holmberg, L. Gillett, C.E. Grigoriadis, A. Purushotham, A. (2017). Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study. Breast cancer research : bcr, Vol.19 (1), pp. 113-?.  show abstract

Yates, L.R. Knappskog, S. Wedge, D. Farmery, J.H. Gonzalez, S. Martincorena, I. Alexandrov, L.B. Van Loo, P. Haugland, H.K. Lilleng, P.K. Gundem, G. Gerstung, M. Pappaemmanuil, E. Gazinska, P. Bhosle, S.G. Jones, D. Raine, K. Mudie, L. Latimer, C. Sawyer, E. Desmedt, C. Sotiriou, C. Stratton, M.R. Sieuwerts, A.M. Lynch, A.G. Martens, J.W. Richardson, A.L. Tutt, A. Lonning, P.E. Campbell, P.J. (2017). Genomic Evolution of Breast Cancer Metastasis and Relapse. Cancer cell, Vol.32 (2), pp. 169-+.

Eisenblaetter, M. Flores-Borja, F. Lee, J.J. Wefers, C. Smith, H. Hueting, R. Cooper, M.S. Blower, P.J. Patel, D. Rodriguez-Justo, M. Milewicz, H. Vogl, T. Roth, J. Tutt, A. Schaeffter, T. Ng, T. (2017). Visualization of Tumor-Immune Interaction - Target-Specific Imaging of S100A8/A9 Reveals Pre-Metastatic Niche Establishment. Theranostics, Vol.7 (9), pp. 2392-2401.

Ju, Y.S. Martincorena, I. Gerstung, M. Petljak, M. Alexandrov, L.B. Rahbari, R. Wedge, D.C. Davies, H.R. Ramakrishna, M. Fullam, A. Martin, S. Alder, C. Patel, N. Gamble, S. O'Meara, S. Giri, D.D. Sauer, T. Pinder, S.E. Purdie, C.A. Borg, Å. Stunnenberg, H. van de Vijver, M. Tan, B.K. Caldas, C. Tutt, A. Ueno, N.T. van 't Veer, L.J. Martens, J.W. Sotiriou, C. Knappskog, S. Span, P.N. Lakhani, S.R. Eyfjörd, J.E. Børresen-Dale, A.-. Richardson, A. Thompson, A.M. Viari, A. Hurles, M.E. Nik-Zainal, S. Campbell, P.J. Stratton, M.R. (2017). Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. Nature, Vol.543 (7647), pp. 714-718.  show abstract

Fittall, M.W. Cheung, A. Petranyi, G.M. Rodriguez-Dominguez, D. Bax, H.J. Karagiannis, P. Ilieva, K.M. Tutt, A. Karagiannis, S.N. (2016). Abstract A090: Exploring folate receptor α immunotherapy of breast carcinomas: Human monocytic cell-mediated killing triggered by IgG1 and IgE antibodies. Cancer immunology research, Vol.4 (1_Supplement), pp. A090-A090.  show abstract

Fittall, M.W. Levi, D. Clifford, A. Shah, V. Cheung, A. Tutt, A. Karagiannis, S.N. (2016). Abstract A089: The circulating memory B cell compartment of breast cancer patients is depleted in comparison with healthy volunteers. Cancer immunology research, Vol.4 (1_Supplement), pp. A089-A089.  show abstract

Flores-Borja, F. Irshad, S. Gordon, P. Wong, F. Sheriff, I. Tutt, A. Ng, T. (2016). Crosstalk between Innate Lymphoid Cells and Other Immune Cells in the Tumor Microenvironment. Journal of immunology research, Vol.2016, pp. ?-? (14).

Marra, P. Mathew, S. Catchpole, S. Facchetti, A. Tutt, A. (2016). Abstract A093: Interferon gamma and post-translational modifications control the dynamics and plasma membrane association of IL15RA expressed by Triple Negative Breast Cancer (TNBC). Cancer immunology research, Vol.4 (1_Supplement), pp. A093-A093.  show abstract

Ju, Y.S. Tubio, J.M. Mifsud, W. Fu, B. Davies, H.R. Ramakrishna, M. Li, Y. Yates, L. Gundem, G. Tarpey, P.S. Behjati, S. Papaemmanuil, E. Martin, S. Fullam, A. Gerstung, M. Nangalia, J. Green, A.R. Caldas, C. Borg, Å. Tutt, A. Lee, M.T. van't Veer, L.J. Tan, B.K. Aparicio, S. Span, P.N. Martens, J.W. Knappskog, S. Vincent-Salomon, A. Børresen-Dale, A.-. Eyfjörd, J.E. Myklebost, O. Flanagan, A.M. Foster, C. Neal, D.E. Cooper, C. Eeles, R. Bova, G.S. Lakhani, S.R. Desmedt, C. Thomas, G. Richardson, A.L. Purdie, C.A. Thompson, A.M. McDermott, U. Yang, F. Nik-Zainal, S. Campbell, P.J. Stratton, M.R. (2016). Corrigendum: Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. Genome research, Vol.26 (5), pp. 717.2-717.2.

Watkins, J. Tutt, A. Grigoriadis, A. (2016). Tandem duplications contribute to not one but two distinct phenotypes. Proc natl acad sci u s a, Vol.113 (36), pp. E5257-E5258.

Nik-Zainal, S. Davies, H. Staaf, J. Ramakrishna, M. Glodzik, D. Zou, X. Martincorena, I. Alexandrov, L.B. Martin, S. Wedge, D.C. Van Loo, P. Ju, Y.S. Smid, M. Brinkman, A.B. Morganella, S. Aure, M.R. Lingjærde, O.C. Langerød, A. Ringnér, M. Ahn, S.-. Boyault, S. Brock, J.E. Broeks, A. Butler, A. Desmedt, C. Dirix, L. Dronov, S. Fatima, A. Foekens, J.A. Gerstung, M. Hooijer, G.K. Jang, S.J. Jones, D.R. Kim, H.-. King, T.A. Krishnamurthy, S. Lee, H.J. Lee, J.-. Li, Y. McLaren, S. Menzies, A. Mustonen, V. O'Meara, S. Pauporté, I. Pivot, X. Purdie, C.A. Raine, K. Ramakrishnan, K. Rodríguez-González, F.G. Romieu, G. Sieuwerts, A.M. Simpson, P.T. Shepherd, R. Stebbings, L. Stefansson, O.A. Teague, J. Tommasi, S. Treilleux, I. Van den Eynden, G.G. Vermeulen, P. Vincent-Salomon, A. Yates, L. Caldas, C. van't Veer, L. Tutt, A. Knappskog, S. Tan, B.K. Jonkers, J. Borg, Å. Ueno, N.T. Sotiriou, C. Viari, A. Futreal, P.A. Campbell, P.J. Span, P.N. Van Laere, S. Lakhani, S.R. Eyfjord, J.E. Thompson, A.M. Birney, E. Stunnenberg, H.G. van de Vijver, M.J. Martens, J.W. Børresen-Dale, A.-. Richardson, A.L. Kong, G. Thomas, G. Stratton, M.R. (2016). Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature, Vol.534 (7605), pp. 47-54.  show abstract

Brasó-Maristany, F. Filosto, S. Catchpole, S. Marlow, R. Quist, J. Francesch-Domenech, E. Plumb, D.A. Zakka, L. Gazinska, P. Liccardi, G. Meier, P. Gris-Oliver, A. Cheang, M.C. Perdrix-Rosell, A. Shafat, M. Noël, E. Patel, N. McEachern, K. Scaltriti, M. Castel, P. Noor, F. Buus, R. Mathew, S. Watkins, J. Serra, V. Marra, P. Grigoriadis, A. Tutt, A.N. (2016). PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nature medicine, Vol.22 (11), pp. 1303-1313.  show abstract

Watkins, J. Weekes, D. Shah, V. Gazinska, P. Joshi, S. Sidhu, B. Gillett, C. Pinder, S. Vanoli, F. Jasin, M. Mayrhofer, M. Isaksson, A. Cheang, M.C. Mirza, H. Frankum, J. Lord, C.J. Ashworth, A. Vinayak, S. Ford, J.M. Telli, M.L. Grigoriadis, A. Tutt, A.N. (2015). Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. Cancer discovery, Vol.5 (5), pp. 488-505.  show abstract

Vollan, H.K. Rueda, O.M. Chin, S.-. Curtis, C. Turashvili, G. Shah, S. Lingjaerde, O.C. Yuan, Y. Ng, C.K. Dunning, M.J. Dicks, E. Provenzano, E. Sammut, S. McKinney, S. Ellis, I.O. Pinder, S. Purushotham, A. Murphy, L.C. Kristensen, V.N. Brenton, J.D. Pharoah, P.D. Børresen-Dale, A.-. Aparicio, S. Caldas, C. (2015). A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. Molecular oncology, Vol.9 (1), pp. 115-127.

Tutt, A. (2015). PG 5 02 Targeting DNA repair pathways. The breast, Vol.24, pp. S9-S10.

Kunkler, I.H. Williams, L.J. Jack, W.J. Cameron, D.A. Dixon, J.M. (2015). Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. The lancet oncology, Vol.16 (3), pp. 266-273.

Soady, K.J. Kendrick, H. Gao, Q. Tutt, A. Zvelebil, M. Ordonez, L.D. Quist, J. Tan, D.W. Isacke, C.M. Grigoriadis, A. Smalley, M.J. (2015). Mouse mammary stem cells express prognostic markers for triple-negative breast cancer. Breast cancer research : bcr, Vol.17, pp. 31-?.  show abstract

Ju, Y.S. Tubio, J.M. Mifsud, W. Fu, B. Davies, H.R. Ramakrishna, M. Li, Y. Yates, L. Gundem, G. Tarpey, P.S. Behjati, S. Papaemmanuil, E. Martin, S. Fullam, A. Gerstung, M. Nangalia, J. Green, A.R. Caldas, C. Borg, Å. Tutt, A. Lee, M.T. van't Veer, L.J. Tan, B.K. Aparicio, S. Span, P.N. Martens, J.W. Knappskog, S. Vincent-Salomon, A. Børresen-Dale, A.-. Eyfjörd, J.E. Myklebost, O. Flanagan, A.M. Foster, C. Neal, D.E. Cooper, C. Eeles, R. Bova, G.S. Lakhani, S.R. Desmedt, C. Thomas, G. Richardson, A.L. Purdie, C.A. Thompson, A.M. McDermott, U. Yang, F. Nik-Zainal, S. Campbell, P.J. Stratton, M.R. (2015). Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. Genome research, Vol.25 (6), pp. 814-824.  show abstract

Schouten, P.C. Grigoriadis, A. Kuilman, T. Mirza, H. Watkins, J.A. Cooke, S.A. van Dyk, E. Severson, T.M. Rueda, O.M. Hoogstraat, M. Verhagen, C.V. Natrajan, R. Chin, S.-. Lips, E.H. Kruizinga, J. Velds, A. Nieuwland, M. Kerkhoven, R.M. Krijgsman, O. Vens, C. Peeper, D. Nederlof, P.M. Caldas, C. Tutt, A.N. Wessels, L.F. Linn, S.C. (2015). Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms. Molecular oncology, Vol.9 (7), pp. 1274-1286.

Di Leo, A. Curigliano, G. Diéras, V. Malorni, L. Sotiriou, C. Swanton, C. Thompson, A. Tutt, A. Piccart, M. (2015). New approaches for improving outcomes in breast cancer in Europe. The breast, Vol.24 (4), pp. 321-330.

Coates, A.S. Winer, E.P. Goldhirsch, A. Gelber, R.D. Gnant, M. Piccart-Gebhart, M. Thürlimann, B. Senn, H.-. André, F. Baselga, J. Bergh, J. Bonnefoi, H. Burstein, H. Cardoso, F. Castiglione-Gertsch, M. Coates, A.S. Colleoni, M. Curigliano, G. Davidson, N.E. Di Leo, A. Ejlertsen, B. Forbes, J.F. Galimberti, V. Gelber, R.D. Gnant, M. Goldhirsch, A. Goodwin, P. Harbeck, N. Hayes, D.F. Huober, J. Hudis, C.A. Ingle, J.N. Jassem, J. Jiang, Z. Karlsson, P. Morrow, M. Orecchia, R. Kent Osborne, C. Partridge, A.H. de la Peña, L. Piccart-Gebhart, M.J. Pritchard, K.I. Rutgers, E.J. Sedlmayer, F. Semiglazov, V. Shao, Z.-. Smith, I. Thürlimann, B. Toi, M. Tutt, A. Viale, G. von Minckwitz, G. Watanabe, T. Whelan, T. Winer, E.P. Xu, B. (2015). Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of oncology, Vol.26 (8), pp. 1533-1546.

Tutt, A. (2015). IN16 RESURRECTING PARP INHIBITION. The breast, Vol.24, pp. S27-S27.

Tsang, Y. Ciurlionis, L. Kirby, A.M. Locke, I. Venables, K. Yarnold, J.R. Titley, J. Bliss, J. Coles, C.E. (2015). Clinical impact of IMPORT HIGH trial (CRUK/06/003) on breast radiotherapy practices in the United Kingdom. The british journal of radiology, Vol.88 (1056), pp. 20150453-20150453.

Lord, C.J. Tutt, A.N. Ashworth, A. (2015). Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors. Annual review of medicine, Vol.66 (1), pp. 455-470.  show abstract

Johnson, P. Challis, R. Chowdhury, F. Gao, Y. Harvey, M. Geldart, T. Kerr, P. Chan, C. Smith, A. Steven, N. Edwards, C. Ashton-Key, M. Hodges, E. Tutt, A. Ottensmeier, C. Glennie, M. Williams, A. (2015). Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study. Clinical cancer research, Vol.21 (6), pp. 1321-1328.  show abstract

Marra, P. Mathew, S. Grigoriadis, A. Wu, Y. Kyle-Cezar, F. Watkins, J. Rashid, M. De Rinaldis, E. Hessey, S. Gazinska, P. Hayday, A. Tutt, A. (2014). IL15RA Drives Antagonistic Mechanisms of Cancer Development and Immune Control in Lymphocyte-Enriched Triple-Negative Breast Cancers. Cancer research, Vol.74 (17), pp. 4908-4921.

Irshad, S. Gillett, C. Pinder, S.E. A'hern, R.P. Dowsett, M. Ellis, I.O. Bartlett, J.M. Bliss, J.M. Hanby, A. Johnston, S. Barrett-Lee, P. Ellis, P. Tutt, A. (2014). Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer. Breast cancer res treat, Vol.144 (2), pp. 331-341.  show abstract

Watkins, J.A. Irshad, S. Grigoriadis, A. Tutt, A.N. (2014). Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast cancer research, Vol.16 (3).

Parikh, J. Selmi, M. Charles-Edwards, G. Glendenning, J. Ganeshan, B. Verma, H. Mansi, J. Harries, M. Tutt, A. Goh, V. (2014). Changes in Primary Breast Cancer Heterogeneity May Augment Midtreatment MR Imaging Assessment of Response to Neoadjuvant Chemotherapy. Radiology, Vol.272 (1), pp. 100-112.

Vantourout, P. Willcox, C. Turner, A. Swanson, C.M. Haque, Y. Sobolev, O. Grigoriadis, A. Tutt, A. Hayday, A. (2014). Immunological Visibility: Posttranscriptional Regulation of Human NKG2D Ligands by the EGF Receptor Pathway. Science translational medicine, Vol.6 (231).

Kyle, F. Hessey, S. Wu, Y. Tutt, A. Hayday, A. (2014). Characterising the immune landscape of healthy breast tissue and breast tumours in humans. Immunology, Vol.143, pp. 144-144.

Kiuchi, T. Ortiz-Zapater, E. Monypenny, J. Matthews, D.R. Nguyen, L.K. Barbeau, J. Coban, O. Lawler, K. Burford, B. Rolfe, D.J. de Rinaldis, E. Dafou, D. Simpson, M.A. Woodman, N. Pinder, S. Gillett, C.E. Devauges, V. Poland, S.P. Fruhwirth, G. Marra, P. Boersma, Y.L. Plueckthun, A. Gullick, W.J. Yarden, Y. Santis, G. Winn, M. Kholodenko, B.N. Martin-Fernandez, M.L. Parker, P. Tutt, A. Ameer-Beg, S.M. Ng, T. (2014). The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility. Science signaling, Vol.7 (339).

Marlow, R. Honeth, G. Lombardi, S. Cariati, M. Hessey, S. Pipili, A. Mariotti, V. Buchupalli, B. Foster, K. Bonnet, D. Grigoriadis, A. Rameshwar, P. Purushotham, A. Tutt, A. Dontu, G. (2013). A Novel Model of Dormancy for Bone Metastatic Breast Cancer Cells. Cancer research, Vol.73 (23), pp. 6886-6899.

Jack, R.H. Davies, E.A. Renshaw, C. Tutt, A. Grocock, M.J. Coupland, V.H. Moller, H. (2013). Differences in breast cancer hormone receptor status in ethnic groups: A London population. European journal of cancer, Vol.49 (3), pp. 696-702.

Eccles, S.A. Aboagye, E.O. Ali, S. Anderson, A.S. Armes, J. Berditchevski, F. Blaydes, J.P. Brennan, K. Brown, N.J. Bryant, H.E. Bundred, N.J. Burchell, J.M. Campbell, A.M. Carroll, J.S. Clarke, R.B. Coles, C.E. Cook, G.J. Cox, A. Curtin, N.J. Dekker, L.V. dos Santos Silva, I. Duffy, S.W. Easton, D.F. Eccles, D.M. Edwards, D.R. Edwards, J. Evans, D.G. Fenlon, D.F. Flanagan, J.M. Foster, C. Gallagher, W.M. Garcia-Closas, M. Gee, J.M. Gescher, A.J. Goh, V. Groves, A.M. Harvey, A.J. Harvie, M. Hennessy, B.T. Hiscox, S. Holen, I. Howell, S.J. Howell, A. Hubbard, G. Hulbert-Williams, N. Hunter, M.S. Jasani, B. Jones, L.J. Key, T.J. Kirwan, C.C. Kong, A. Kunkler, I.H. Langdon, S.P. Leach, M.O. Mann, D.J. Marshall, J.F. Martin, L.A. Martin, S.G. Macdougall, J.E. Miles, D.W. Miller, W.R. Morris, J.R. Moss, S.M. Mullan, P. Natrajan, R. O’Connor, J.P. O’Connor, R. Palmieri, C. Pharoah, P.D. Rakha, E.A. Reed, E. Robinson, S.P. Sahai, E. Saxton, J.M. Schmid, P. Smalley, M.J. Speirs, V. Stein, R. Stingl, J. Streuli, C.H. Tutt, A.N. Velikova, G. Walker, R.A. Watson, C.J. Williams, K.J. Young, L.S. Thompson, A.M. (2013). Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast cancer research, Vol.15 (5).

Alexandrov, L.B. Nik-Zainal, S. Wedge, D.C. Aparicio, S.A. Behjati, S. Biankin, A.V. Bignell, G.R. Bolli, N. Borg, A. Børresen-Dale, A.-. Boyault, S. Burkhardt, B. Butler, A.P. Caldas, C. Davies, H.R. Desmedt, C. Eils, R. Eyfjörd, J.E. Foekens, J.A. Greaves, M. Hosoda, F. Hutter, B. Ilicic, T. Imbeaud, S. Imielinski, M. Jäger, N. Jones, D.T. Jones, D. Knappskog, S. Kool, M. Lakhani, S.R. López-Otín, C. Martin, S. Munshi, N.C. Nakamura, H. Northcott, P.A. Pajic, M. Papaemmanuil, E. Paradiso, A. Pearson, J.V. Puente, X.S. Raine, K. Ramakrishna, M. Richardson, A.L. Richter, J. Rosenstiel, P. Schlesner, M. Schumacher, T.N. Span, P.N. Teague, J.W. Totoki, Y. Tutt, A.N. Valdés-Mas, R. van Buuren, M.M. van ’t Veer, L. Vincent-Salomon, A. Waddell, N. Yates, L.R. Zucman-Rossi, J. Andrew Futreal, P. McDermott, U. Lichter, P. Meyerson, M. Grimmond, S.M. Siebert, R. Campo, E. Shibata, T. Pfister, S.M. Campbell, P.J. Stratton, M.R. (2013). Signatures of mutational processes in human cancer. Nature, Vol.500 (7463), pp. 415-421.

Yau, C. Sninsky, J. Kwok, S. Wang, A. Degnim, A. Ingle, J.N. Gillett, C. Tutt, A. Waldman, F. Moore, D. Esserman, L. Benz, C.C. (2013). An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk. Breast cancer research, Vol.15 (5).

Kaufmann, M. von Minckwitz, G. Mamounas, E.P. Cameron, D. Carey, L.A. Cristofanilli, M. Denkert, C. Eiermann, W. Gnant, M. Harris, J.R. Karn, T. Liedtke, C. Mauri, D. Rouzier, R. Ruckhaeberle, E. Semiglazov, V. Symmans, W.F. Tutt, A. Pusztai, L. (2012). Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. Annals of surgical oncology, Vol.19 (5), pp. 1508-1516.

Vichapat, V. Garmo, H. Holmberg, L. Fentiman, I.S. Tutt, A. Gillett, C. Luechtenborg, M. (2012). Patterns of metastasis in women with metachronous contralateral breast cancer. British journal of cancer, Vol.107 (2), pp. 221-223.

Tutt, A. (2012). The biology of BRCA-associated breast cancer. Breast, Vol.21, pp. S2-S2.

Turner, N.C. Tutt, A.N. (2012). Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?. Breast cancer research, Vol.14 (6).

Robertson, L. Hanson, H. Seal, S. Warren-Perry, M. Hughes, D. Howell, I. Turnbull, C. Houlston, R. Shanley, S. Butler, S. Evans, D.G. Ross, G. Eccles, D. Tutt, A. Rahman, N. TNT Trial TMG, BCSC (UK), (2012). BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br j cancer, Vol.106 (6), pp. 1234-1238.  show abstract

Grigoriadis, A. Mackay, A. Noel, E. Wu, P.J. Natrajan, R. Frankum, J. Reis-Filho, J.S. Tutt, A. (2012). Molecular characterisation of cell line models for triple-negative breast cancers. Bmc genomics, Vol.13.

Marlow, R. Cariati, M. Honeth, G.M. Buchupalli, B. Lombardi, S. Foster, K. Bonnet, D. Purushotham, A. Tutt, A. Dontu, G. (2012). Abstract LB-307: Modeling the breast cancer metastatic niche. Cancer research, Vol.72 (8_Supplement).  show abstract

Metzger-Filho, O. Tutt, A. de Azambuja, E. Saini, K.S. Viale, G. Loi, S. Bradbury, I. Bliss, J.M. Azim, H.A. Ellis, P. Di Leo, A. Baselga, J. Sotiriou, C. Piccart-Gebhart, M. (2012). Dissecting the heterogeneity of triple-negative breast cancer. J clin oncol, Vol.30 (15), pp. 1879-1887.  show abstract

Stephens, P.J. Tarpey, P.S. Davies, H. Van Loo, P. Greenman, C. Wedge, D.C. Nik-Zainal, S. Martin, S. Varela, I. Bignell, G.R. Yates, L.R. Papaemmanuil, E. Beare, D. Butler, A. Cheverton, A. Gamble, J. Hinton, J. Jia, M. Jayakumar, A. Jones, D. Latimer, C. Lau, K.W. McLaren, S. McBride, D.J. Menzies, A. Mudie, L. Raine, K. Rad, R. Chapman, M.S. Teague, J. Easton, D. Langerod, A. Lee, M.T. Shen, C.-. Tee, B.T. Huimin, B.W. Broeks, A. Vargas, A.C. Turashvili, G. Martens, J. Fatima, A. Miron, P. Chin, S.-. Thomas, G. Boyault, S. Mariani, O. Lakhani, S.R. van de Vijver, M. Van 'tVeer, L. Foekens, J. Desmedt, C. Sotiriou, C. Tutt, A. Caldas, C. Reis-Filho, J.S. Aparicio, S.A. Salomon, A.V. Borresen-Dale, A.-. Richardson, A.L. Campbell, P.J. Futreal, P.A. Stratton, M.R. OSBREAC, (2012). The landscape of cancer genes and mutational processes in breast cancer. Nature, Vol.486 (7403), pp. 400-+.

Nik-Zainal, S. Van Loo, P. Wedge, D.C. Alexandrov, L.B. Greenman, C.D. Lau, K.W. Raine, K. Jones, D. Marshall, J. Ramakrishna, M. Shlien, A. Cooke, S.L. Hinton, J. Menzies, A. Stebbings, L.A. Leroy, C. Jia, M. Rance, R. Mudie, L.J. Gamble, S.J. Stephens, P.J. McLaren, S. Tarpey, P.S. Papaemmanuil, E. Davies, H.R. Varela, I. McBride, D.J. Bignell, G.R. Leung, K. Butler, A.P. Teague, J.W. Martin, S. Joensson, G. Mariani, O. Boyault, S. Miron, P. Fatima, A. Langerod, A. Aparicio, S.A. Tutt, A. Sieuwerts, A.M. Borg, A. Thomas, G. Salomon, A.V. Richardson, A.L. Borresen-Dale, A.-. Futreal, P.A. Stratton, M.R. Campbell, P.J. Consortium, I.C. (2012). The Life History of 21 Breast Cancers. Cell, Vol.149 (5).

Nik-Zainal, S. Alexandrov, L.B. Wedge, D.C. Van Loo, P. Greenman, C.D. Raine, K. Jones, D. Hinton, J. Marshall, J. Stebbings, L.A. Menzies, A. Martin, S. Leung, K. Chen, L. Leroy, C. Ramakrishna, M. Rance, R. Lau, K.W. Mudie, L.J. Varela, I. McBride, D.J. Bignell, G.R. Cooke, S.L. Shlien, A. Gamble, J. Whitmore, I. Maddison, M. Tarpey, P.S. Davies, H.R. Papaemmanuil, E. Stephens, P.J. McLaren, S. Butler, A.P. Teague, J.W. Jonsson, G. Garber, J.E. Silver, D. Miron, P. Fatima, A. Boyault, S. Langerod, A. Tutt, A. Martens, J.W. Aparicio, S.A. Borg, A. Salomon, A.V. Thomas, G. Borresen-Dale, A.-. Richardson, A.L. Neuberger, M.S. Futreal, P.A. Campbell, P.J. Stratton, M.R. Consortium, I.C. (2012). Mutational Processes Molding the Genomes of 21 Breast Cancers. Cell, Vol.149 (5), pp. 979-993.

Irshad, S. Grigoriadis, A. Lawler, K. Ng, T. Tutt, A. (2012). Profiling the Immune Stromal Interface in Breast Cancer and Its Potential for Clinical Impact. Breast care, Vol.7 (4), pp. 273-280.

Tutt, A. (2011). PARP inhibitors - walking them through to adjuvant. Breast, Vol.20, pp. S1-S1.

Balmana, J. Domchek, S.M. Tutt, A. Garber, J.E. (2011). Stumbling Blocks on the Path to Personalized Medicine in Breast Cancer: The Case of PARP Inhibitors for BRCA1/2-Associated Cancers. Cancer discovery, Vol.1 (1), pp. 29-34.

Irshad, S. Ashworth, A. Tutt, A. (2011). Therapeutic potential of PARP inhibitors for metastatic breast cancer. Expert review of anticancer therapy, Vol.11 (8), pp. 1243-1251.

Vichapat, V. Gillett, C. Fentiman, I.S. Tutt, A. Holmberg, L. Luechtenborg, M. (2011). Risk factors for metachronous contralateral breast cancer suggest two aetiological pathways. European journal of cancer, Vol.47 (13), pp. 1919-1927.

Tutt, A. (2011). ROLE OF PARP INHIBITORS IN TN ADVANCED BREAST CANCER. Breast, Vol.20, pp. S17-S17.

Glendenning, J. Tutt, A. (2011). PARP inhibitors - current status and the walk towards early breast cancer. Breast, Vol.20, pp. S12-S19.

Domchek, S.M. Mitchell, G. Lindeman, G.J. Tung, N.M. Balmana, J. Isakoff, S.J. Schmutzler, R. Audeh, M.W. Loman, N. Scott, C. Friedlander, M. Kaufman, B. Garber, J.E. Tutt, A. Robson, M.E. (2011). Challenges to the Development of New Agents for Molecularly Defined Patient Subsets: Lessons From BRCA1/2-Associated Breast Cancer. Journal of clinical oncology, Vol.29 (32), pp. 4224-4226.

Irshad, S. Ellis, P. Tutt, A. (2011). Molecular heterogeneity of triple-negative breast cancer and its clinical implications. Current opinion in oncology, Vol.23 (6), pp. 566-577.

Vichapat, V. Garmo, H. Holmberg, L. Fentiman, I.S. Tutt, A. Gillett, C. Luechtenborg, M. (2011). Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses. Breast cancer research and treatment, Vol.130 (2), pp. 609-618.

Julien, S. Ivetic, A. Grigoriadis, A. Qize, D. Burford, B. Sproviero, D. Picco, G. Gillett, C. Papp, S.L. Schaffer, L. Tutt, A. Taylor-Papadimitriou, J. Pinder, S.E. Burchell, J.M. (2011). Selectin Ligand Sialyl-Lewis x Antigen Drives Metastasis of Hormone-Dependent Breast Cancers. Cancer research, Vol.71 (24), pp. 7683-7693.

Tutt, A. (2011). Abstract PL04-02: Synthetic lethality: Targeting DNA repair mechanisms in clinical trials. Cancer research, Vol.71 (8_Supplement).  show abstract

Jiao, Y. Lawler, K. Patel, G.S. Purushotham, A. Jones, A.F. Grigoriadis, A. Tutt, A. Ng, T. Teschendorff, A.E. (2011). DART: Denoising Algorithm based on Relevance network Topology improves molecular pathway activity inference. Bmc bioinformatics, Vol.12.

Basu, B. Ang, J.E. Crawley, D. Folkerd, E. Sarker, D. Blanco-Codesido, M. Moran, K. Wan, S. Dobbs, N. Raynaud, F. Johnston, S.R. Dowsett, M. Tutt, A.N. Spicer, J.F. Swanton, C. De Bono, J.S. (2011). Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor- (ER) or androgen receptor (AR) -positive advanced breast carcinoma resistant to standard endocrine therapies. J clin oncol, Vol.29 (15_suppl), p. 2525.  show abstract

Basu, B. Ang, J.E. Crawley, D. Folkerd, E. Sarker, D. Blanco-Codesido, M. Moran, K. Wan, S. Dobbs, N. Raynaud, F. Johnston, S.R. Dowsett, M. Tutt, A.N. Spicer, J.F. Swanton, C. De Bono, J.S. (2011). Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor-(ER) or androgen receptor (AR)-positive advanced breast carcinoma resistant to standard endocrine therapies. Journal of clinical oncology, Vol.29 (15).

Turner, N. Pearson, A. Sharpe, R. Lambros, M. Geyer, F. Lopez-Garcia, M.A. Natrajan, R. Marchio, C. Iorns, E. Mackay, A. Gillett, C. Grigoriadis, A. Tutt, A. Reis-Filho, J.S. Ashworth, A. (2010). FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer. Cancer research, Vol.70 (5), pp. 2085-10.

Yap, T.A. de Bono, J.S. Kaye, S.B. Tutt, A. Ashworth, A. Schellens, J.H. (2010). Reply to J Veeck et al. J clin oncol, .

Molyneux, G. Geyer, F.C. Magnay, F.-. McCarthy, A. Kendrick, H. Natrajan, R. Mackay, A. Grigoriadis, A. Tutt, A. Ashworth, A. Reis-Filho, J.S. Smalley, M.J. (2010). BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell stem cell, Vol.7 (3), pp. 403-417.  show abstract

Stebbing, J. Ellis, P. Tutt, A. (2010). PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers. Future oncology, Vol.6 (4), pp. 485-486.

Pichert, G. Jacobs, C. Jacobs, I. Menon, U. Manchanda, R. Johnson, M. Hamed, H. Firth, C. Evison, M. Tutt, A. de Silva, L. Langman, C. Izatt, L. (2010). Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1/2 carriers. Familial cancer, Vol.9 (3), pp. 313-319.

Cazet, A. Lefebvre, J. Adriaenssens, E. Julien, S. Bobowski, M. Grigoriadis, A. Tutt, A. Tulasne, D. Le Bourhis, X. Delannoy, P. (2010). G(D3) Synthase Expression Enhances Proliferation and Tumor Growth of MDA-MB-231 Breast Cancer Cells through c-Met Activation. Molecular cancer research, Vol.8 (11), pp. 1526-1535.

Fong, P.C. Yap, T.A. Boss, D.S. Carden, C.P. Mergui-Roelvink, M. Gourley, C. De Greve, J. Lubinski, J. Shanley, S. Messiou, C. A'Hern, R. Tutt, A. Ashworth, A. Stone, J. Carmichael, J. Schellens, J.H. de Bono, J.S. Kaye, S.B. (2010). Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J clin oncol, Vol.28 (15), pp. 2512-2519.  show abstract

Uva, P. Lahm, A. Sbardellati, A. Grigoriadis, A. Tutt, A. de Rinaldis, E. (2010). Comparative Membranome Expression Analysis in Primary Tumors and Derived Cell Lines. Plos one, Vol.5 (7).

Tutt, A. Robson, M. Garber, J.E. Domchek, S.M. Audeh, M.W. Weitzel, J.N. Friedlander, M. Arun, B. Loman, N. Schmutzler, R.K. Wardley, A. Mitchell, G. Earl, H. Wickens, M. Carmichael, J. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet, Vol.376 (9737), pp. 235-244.

Audeh, M.W. Carmichael, J. Penson, R.T. Friedlander, M. Powell, B. Bell-McGuinn, K.M. Scott, C. Weitzel, J.N. Oaknin, A. Loman, N. Lu, K. Schmutzler, R.K. Matulonis, U. Wickens, M. Tutt, A. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet, Vol.376 (9737), pp. 245-251.

Iverson, A.A. Gillett, C. Cane, P. Santini, C.D. Vess, T.M. Kam-Morgan, L. Wang, A. Eisenberg, M. Rowland, C.M. Hessling, J.J. Broder, S.E. Sninsky, J.J. Tutt, A. Anderson, S. Chang, S.-. (2009). A Single-Tube Quantitative Assay for mRNA Levels of Hormonal and Growth Factor Receptors in Breast Cancer Specimens. Journal of molecular diagnostics, Vol.11 (2), pp. 117-130.

Loi, S. Haibe-Kains, B. Lallemand, F. Pusztai, L. Tutt, A. Gillett, C.E. Piccart, M. Phillips, W.A. McArthur, G. Sotiriou, C. (2009). PIK3CA, AKT1 MUTATION AND HER2 AMPLIFICATION GENE SIGNATURES (GS) SUGGEST PREDOMINANTLY NEGATIVE FEEDBACK INHIBITION OF PI3K/AKT PATHWAY IN HUMAN BREAST CANCER (BC). Annals of oncology, Vol.20, pp. 45-45.

Rhiem, K. Wappenschmidt, B. Bosse, K. Koeppler, H. Tutt, A.N. Schmutzler, R.K. (2009). Platinum Sensitivity in a BRCA1 Mutation Carrier with Advanced Breast Cancer. Clinical oncology, Vol.21 (6), pp. 448-450.

Fong, P.C. Boss, D.S. Yap, T.A. Tutt, A. Wu, P. Mergui-Roelvink, M. Mortimer, P. Swaisland, H. Lau, A. O'Connor, M.J. Ashworth, A. Carmichael, J. Kaye, S.B. Schellens, J.H. de Bono, J.S. (2009). Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N engl j med, Vol.361 (2), pp. 123-134.  show abstract

Natrajan, R. Lambros, M.B. Rodríguez-Pinilla, S.M. Moreno-Bueno, G. Tan, D.S. Marchió, C. Vatcheva, R. Rayter, S. Mahler-Araujo, B. Fulford, L.G. Hungermann, D. Mackay, A. Grigoriadis, A. Fenwick, K. Tamber, N. Hardisson, D. Tutt, A. Palacios, J. Lord, C.J. Buerger, H. Ashworth, A. Reis-Filho, J.S. (2009). Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers. Clinical cancer research, Vol.15 (8), pp. 2711-2722.  show abstract

Tutt, A. Robson, M. Garber, J.E. Domchek, S. Audeh, M.W. Weitzel, J.N. Friedlander, M. Carmichael, J. (2009). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J clin oncol, Vol.27 (18_suppl), p. CRA501.  show abstract

Tutt, A. Robson, M. Garber, J.E. Domchek, S. Audeh, M.W. Weitzel, J.N. Friedlander, M. Carmichael, J. (2009). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J clin oncol, Vol.27 (15_suppl), p. CRA501.  show abstract

Tutt, A. Ashworth, A. (2008). Can genetic testing guide treatment in breast cancer?. European journal of cancer, Vol.44 (18), pp. 2774-7.

Reis-Filho, J.S. Tutt, A.N. (2008). Triple negative tumours: a critical review. Histopathology, Vol.52 (1), pp. 108-118.  show abstract

Iorns, E. Turner, N.C. Elliott, R. Syed, N. Garrone, O. Gasco, M. Tutt, A.N. Crook, T. Lord, C.J. Ashworth, A. (2008). Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer. Cancer cell, Vol.13 (2), pp. 91-104.

Turner, N.C. Lord, C.J. Iorns, E. Brough, R. Swift, S. Elliott, R. Rayter, S. Tutt, A.N. Ashworth, A. (2008). A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. Embo journal, Vol.27 (9), pp. 1368-10.

Tutt, A. Wang, A. Rowland, C. Gillett, C. Lau, K. Chew, K. Dai, H. Kwok, S. Ryder, K. Shu, H. Springall, R. Cane, P. McCallie, B. Kam-Morgan, L. Anderson, S. Buerger, H. Gray, J. Bennington, J. Esserman, L. Hastie, T. Broder, S. Sninsky, J. Brandt, B. Waldman, F. (2008). Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. Bmc cancer, Vol.8.

Hiley, C. Tutt, A. Torres, M. Palmieri, C. (2008). Adjuvant radiotherapy for breast cancer. British medical journal, Vol.337.

Turner, N.C. Reis-Filho, J.S. Russell, A.M. Springall, R.J. Ryder, K. Steele, D. Savage, K. Gillett, C.E. Schmitt, F.C. Ashworth, A. Tutt, A.N. (2007). BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene, Vol.26 (14), pp. 2126-2132.

Rakha, E.A. Tan, D.S. Foulkes, W.D. Ellis, I.O. Tutt, A. Nielsen, T.O. Reis-Filho, J.S. (2007). Are triple-negative tumours and basal-like breast cancer synonymous?. Breast cancer res, Vol.9 (6), p. 404.

Shanley, S. McReynolds, K. Ardern-Jones, A. Ahern, R. Fernando, I. Yarnold, J. Evans, G. Eccles, D. Hodgson, S. Ashley, S. Ashcroft, L. Tutt, A. Bancroft, E. Short, S. Gui, G. Barr, L. Baildam, A. Howell, A. Royle, G. Pierce, L. Easton, D. Eeles, R. (2006). Late Toxicity Is Not Increased in BRCA1/BRCA2 Mutation Carriers Undergoing Breast Radiotherapy in the United Kingdom. Clinical cancer research, Vol.12 (23), pp. 7025-7032.  show abstract

Shanley, S. McReynolds, K. Ardern-Jones, A. Ahern, R. Fernando, I. Yarnold, J. Evans, G. Eccles, D. Hodgson, S. Ashley, S. Ashcroft, L. Tutt, A. Bancroft, E. Short, S. Smith, I. Gui, G. Barr, L. Baildam, A. Howell, A. Royle, G. Pierce, L. Easton, D. Eeles, R. (2006). Acute Chemotherapy–Related Toxicity Is Not Increased in BRCA1 and BRCA2 Mutation Carriers Treated for Breast Cancer in the United Kingdom. Clinical cancer research, Vol.12 (23), pp. 7033-7038.  show abstract

Tutt, A. Yarnold, J. (2006). Radiobiology of Breast Cancer. Clinical oncology, Vol.18 (3), pp. 166-178.

de Bono, J.S. Fong, P.C. Boss, D. Spicer, J. Roelvink, M. Tutt, A. Mortimer, P. O'Connor, M. M, J.H. Kaye, S.B. (2006). 503 POSTER Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evalutation of an oral small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), Ku in patients (p) with advance tumours. European journal of cancer supplements, Vol.4 (12), pp. 153-153.

McCabe, N. Turner, N.C. Lord, C.J. Kluzek, K. Białkowska, A. Swift, S. Giavara, S. O'Connor, M.J. Tutt, A.N. Zdzienicka, M.Z. Smith, G.C. Ashworth, A. (2006). Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition. Cancer research, Vol.66 (16), pp. 8109-8115.  show abstract

Fong, P.C. Spicer, J. Reade, S. Reid, A. Vidal, L. Schellens, J.H. Tutt, A. Harris, P.A. Kaye, S. De Bono, J.S. (2006). Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours. J clin oncol, Vol.24 (18_suppl), p. 3022.  show abstract

Farmer, H. McCabe, N. Lord, C.J. Tutt, A.N. Johnson, D.A. Richardson, T.B. Santarosa, M. Dillon, K.J. Hickson, I. Knights, C. Martin, N.M. Jackson, S.P. Smith, G.C. Ashworth, A. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, Vol.434 (7035), pp. 917-921.

TURNER, N. TUTT, A. ASHWORTH, A. (2005). Targeting the DNA repair defect of BRCA tumours. Current opinion in pharmacology, Vol.5 (4), pp. 388-393.

McCabe, N. Lord, C.J. Tutt, A.N. Martin, N. Smith, G.C. Ashworth, A. (2005). BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: An issue of potency. Cancer biology & therapy, Vol.4 (9), pp. 934-936.

Turner, N. Tutt, A. Ashworth, A. (2004). Hallmarks of 'BRCAness' in sporadic cancers. Nature reviews cancer, Vol.4 (10), pp. 814-819.

Gudmundsdottir, K. Lord, C.J. Witt, E. Tutt, A.N. Ashworth, A. (2004). DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells. Embo reports, Vol.5 (10), pp. 989-993.

Tutt, A. Connor, F. Bertwistle, D. Kerr, P. Peacock, J. Ross, G. Ashworth, A. (2003). Cell cycle and genetic background dependence of the effect of loss of BRCA2 on ionizing radiation sensitivity. Oncogene, Vol.22 (19), pp. 2926-2931.

Tutt, A.N. van Oostrom, C.T. Ross, G.M. van Steeg, H. Ashworth, A. (2002). Disruption of Brca2 increases the spontaneous mutation rate in vivo : synergism with ionizing radiation. Embo reports, Vol.3 (3), pp. 255-260.

Tutt, A. Ashworth, A. (2002). The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends in molecular medicine, Vol.8 (12), pp. 571-576.

Tutt, A. (2001). Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. The embo journal, Vol.20 (17), pp. 4704-4716.

Tutt, A.N. Bertwistle, D. Valentine, J. Gabriel, A. Swift, S. Ross, G.M. Griffin, C. Thacker, J. Ashworth, A. (2001). Mutation in BRCA2 reduces use of error-free DNA repair by sister chromatid recombination and stimulates error-prone DNA repair by homology directed single-strand annealing. Breast cancer research and treatment, Vol.69 (3), pp. 255-255.

Tutt, A. Gabriel, A. Bertwistle, D. Connor, F. Paterson, H. Peacock, J. Ross, G. Ashworth, A. (1999). Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Current biology, Vol.9 (19), pp. 1107-S1.

Tutt, A.N. A'hern, R. Henk, J.M. (1998). Cervical node metastasis of unknown primary site: The Royal Marsden Hospital 15 year experience. British journal of cancer, Vol.78, pp. 6-6.

de Rinaldis, E. Gazinska, P. Mera, A. Modrusan, Z. Fedorowicz, G.M. Burford, B. Gillett, C. Marra, P. Grigoriadis, A. Dornan, D. Holmberg, L. Pinder, S. Tutt, A. Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. Bmc genomics, (14).

Cheung, A. Bax, H.J. Josephs, D.H. Ilieva, K.M. Pellizzari, G. Opzoomer, J. Bloomfield, J. Fittall, M. Grigoriadis, A. Figini, M. Canevari, S. Spicer, J.F. Tutt, A.N. Karagiannis, S.N. Targeting folate receptor alpha for cancer treatment. Oncotarget, Vol.7 (32), pp. 52553-52574.  show abstract

Akre, M.K. Starrett, G.J. Quist, J.S. Temiz, N.A. Carpenter, M.A. Tutt, A.N. Grigoriadis, A. Harris, R.S. Mutation Processes in 293-Based Clones Overexpressing the DNA Cytosine Deaminase APOBEC3B. Plos one, Vol.11 (5), pp. e0155391-e0155391.

Turner, N.C. Balmaña, J. Poncet, C. Goulioti, T. Tryfonidis, K. Honkoop, A.H. Zoppoli, G. Razis, E. Johannsson, O.T. Colleoni, M. Tutt, A.N. Audeh, W. Ignatiadis, M. Mailliez, A. Trédan, O. Musolino, A. Vuylsteke, P. Juan-Fita, M.J. Macpherson, I.R. Kaufman, B. Manso, L. Goldstein, L.J. Ellard, S.L. Láng, I. Jen, K.Y. Adam, V. Litière, S. Erban, J. Cameron, D.A. BRAVO Steering Committee and the BRAVO investigators, Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. Clinical cancer research : an official journal of the american association for cancer research, Vol.27 (20), pp. 5482-5491.  show abstract

Early Breast Cancer Trialists’ Collaborative group (EBCTCG), Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. The lancet. oncology, Vol.22 (8), pp. 1139-1150.  show abstract

Harvey-Jones, E. Vinas Villaro, G. Tutt, A. New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer. Cancer journal (sudbury, mass.), Vol.27 (6), pp. 441-456.  show abstract

Krastev, D.B. Li, S. Sun, Y. Wicks, A.J. Hoslett, G. Weekes, D. Badder, L.M. Knight, E.G. Marlow, R. Pardo, M.C. Yu, L. Talele, T.T. Bartek, J. Choudhary, J.S. Pommier, Y. Pettitt, S.J. Tutt, A.N. Ramadan, K. Lord, C.J. The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin. Nature cell biology, .  show abstract

Beatson, R.E. Parente-Pereira, A.C. Halim, L. Cozzetto, D. Hull, C. Whilding, L.M. Martinez, O. Taylor, C.A. Obajdin, J. Luu Hoang, K.N. Draper, B. Iqbal, A. Hardiman, T. Zabinski, T. Man, F. de Rosales, R.T. Xie, J. Aswad, F. Achkova, D. Joseph, C.-. Ciprut, S. Adami, A. Roider, H.G. Hess-Stumpp, H. Győrffy, B. Quist, J. Grigoriadis, A. Sommer, A. Tutt, A.N. Davies, D.M. Maher, J. TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancer. Cell reports medicine, Vol.2 (12), pp. 100473-100473.

Tutt, A. Tarantino, D. Walker, C. Weekes, D. Pemberton, H. Davidson, K. Torga, G. Frankum, J. Brough, R. Pettitt, S. Lord, C. Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress tolerance. Oncogene, .


Book Chapters

Irshad, S. Tutt, A. (2015). Clinical Trials Investigating PARP Inhibitors as Single Agents. Cancer Drug Discovery and Development. (pp. 487-510). Springer International Publishing, ISBN: 9783319141503.

Yap, T.A. Kaye, S.B. Ashworth, A. Tutt, A. (2011). Tumour specific synthetic lethality: targeting BRCA dysfunction in ovarian cancer. In Kaye, S.B.Brown, R.Gabra, H.Gore, M. (Eds.), Emerging Therapeutic Targets in Ovarian Cancer. (pp. 109-33). New York, Springer Science.


Conferences

Schmid, P.Wheatley, D.Baird, R.Chan, S.Abraham, J.Tutt, A.Kristeleit, H.Patel, G.Bathakur, U.Bishop, J.Harper-Wynne, C.Sims, E.Copson, E.Perren, T.Stein, R.Poole, C.Cartwright, H.Sarker, S.-.Mousa, K.Turner, N. (2016). Abstract OT1-03-13: A phase II, double blind, randomised, placebo-controlled study of the AKT Inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer (TNBC)(NCT02423603), Cancer Research, Vol.76 (4_Supplement).

Ilieva, K.M.Marlow, R.Cheung, A.Francesch, E.Karagiannis, P.Fittall, M.Crescioli, S.Tutt, A.Karagiannis, S. (2015). Abstract 1324: A translational platform to design antibodies targeting triple negative breast cancer-specific antigens for cancer immunotherapy, Cancer Research, Vol.75 (15_Supplement), p.1324.

Robson, M.Tutt, A.Balmaña, J.Kaufman, B.Garber, J.Geyer, C.Ford, J.Sharma, P.Stuart, M.Mann, H.Fasching, P.A. (2015). Abstract OT1-1-04: OlympiA, Neo-Olympia and OlympiAD: Randomized phase III trials of olaparib in patients (pts) with breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm), Cancer Research, Vol.75 (9_Supplement).

Lawler, K.Papouli, E.Tutt, A.Ng, T.Pinder, S.Parker, P.Holmberg, L.Gillett, C.Grigoriadis, A.Purushotham, A. (2015). Clinical patterns of metastatic spread from formalin-fixed, paraffin-embedded (FFPE) expression profiles: A case-control study of 1,357 breast cancer patients, ANNALS OF ONCOLOGY, Vol.26.

Tutt, A. (2014). DESIGNING CLINICAL TRIALS IN A POST NEO-ADJUVANT SETTING, ANNALS OF ONCOLOGY, Vol.25.

Tryfonidis, K.Bogaerts, J.Martell, R.E.Sledge, G.W.Balmaña, J.Audeh, M.W.Deleersnijder, A.Favorito, F.Agarwal, S.Rizzetto, G.Messina, C.G.Slaets, L.Goulioti, T.Tutt, A.Cameron, D.A.Turner, N.C. (2014). A phase III randomized trial of niraparib versus physician’s choice in previously treated, HER2-negative, germline-BRCA mutated breast cancer patients: Intergroup study EORTC-1307-BCG and BIG5-13., Journal of Clinical Oncology, Vol.32 (15_suppl), p.TPS659.

Kyle, F.Wu, Y.Nussbaumer, O.Hessey, S.Tutt, A.Hayday, A. (2013). Characterisation of Tumour-Infiltrating Lymphocytes in primary breast cancer, IMMUNOLOGY, Vol.140, p.19.

A'Hern, R.Gillett, C.Pinder, S.Kalaitzaki, E.Bliss, J.Tutt, A.Barrett-Lee, P.Ellis, P.Johnston, S. (2013). Abstract P6-06-03: Differing patterns of treatment effect in a trial assessing sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT), Cancer Research, Vol.73 (24_Supplement).

Grigoriadis, A.Gazinska, P.Rasmussen, M.Isaksson, A.de Rinaldis, E.Mathew, S.Marra, P.Gillett, C.Pinder, S.Tutt, A. (2012). EXPRESSION OF HORMAD1, A CANCER/TESTIS ANTIGEN, IN TRIPLE-NEGATIVE BREAST CANCERS WITH HIGH GENOMIC INSTABILITY, ANNALS OF ONCOLOGY, Vol.23, p.37.

Sninsky, J.J.Christopherson, C.Lagier, R.Chang, M.Kwok, S.Tandon, V.Moore, D.H.Waldman, F.Degnim, A.C.Ingle, J.N.Yau, C.Benz, C.Gillett, C.Tutt, A.Wang, A.M.Esserman, L. (2012). Multiplex TaqMan assays for a 7-gene prognostic immune response score to differentiate risk among women with ER-negative breast cancer., JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Gazinska, P.Grigoriadis, A.Springall, R.Bosshard-Carter, L.Woodman, N.Rashid, M.deRinaldis, E.Marra, P.Brown, J.Pinder, S.Tutt, A.Gillett, C. (2011). Evaluation of Nucleic Acid Quality From Long-Time Stored Fresh-Frozen Breast Cancer Tissues After Non-Automated Needle Micro-Dissection., JOURNAL OF PATHOLOGY, Vol.224, p.S27.

Marra, P.Twiddy, D.Maristany, F.B.Noel, E.Mathew, S.Gazinska, P.Grigoriadis, A.Rashid, M.de Rinaldis, E.Tutt, A. (2011). IDENTIFICATION AND VALIDATION OF PUTATIVE ONCOGENIC DRIVER GENES IN TRIPLE NEGATIVE BREAST CANCER (TNBC): THE ROLE OF IL15RA, ANNALS OF ONCOLOGY, Vol.22, p.51.

White, A.L.Chan, H.T.French, R.R.Roghanian, A.Mockridge, C.I.Tutt, A.L.Verbeek, J.S.Noelle, R.J.Al-Shamkhani, A.Cragg, M.S.Beers, S.A.Glennie, M.J. (2011). Essential cross-linking role for FcgRIIB in the in vivo activity of anti-CD40 monoclonal antibody, IMMUNOLOGY, Vol.135, p.189.

Tutt, A. (2010). EARLY PHASE PROOF OF CONCEPT STUDIES AND RATIONALE FOR PATIENT SELECTION, ANNALS OF ONCOLOGY, Vol.21, p.22.

Izatt, L.Jacobs, C.Jacobs, I.Menon, U.Manchanda, R.Johnson, M.Hamed, H.Firth, C.Evison, M.Tutt, A.de Silva, L.Langman, C.Picher, G. (2010). Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1/2 carriers, JOURNAL OF MEDICAL GENETICS, Vol.47, p.S116.

Tutt, A. (2010). LATER TALES: PHASE II AND BEYOND, ANNALS OF ONCOLOGY, Vol.21, p.26.

Natrajan, R.Rodriguez-Pinilla, S.M.Lambros, M.B.Tan, D.S.Marchio, C.Vatcheva, R.Rayter, S.Moreno-Bueno, G.Fulford, L.G.Mackay, A.Grigoriadis, A.Fenwick, K.Tamber, N.Hardisson, D.Tutt, A.Palacios, J.Buerger, H.Lord, C.J.Ashworth, A.Reis-Filho, J.S. (2009). Molecular Profiling of Grade III Invasive Ductal Breast Cancers Identifies PPM1D Amplification as a Therapeutic Target in Luminal and HER2 Tumours, LABORATORY INVESTIGATION, Vol.89, p.59A.

Natrajan, R.Rodriguez-Pinilla, S.M.Lambros, M.B.Tan, D.S.Marchio, C.Vatcheva, R.Rayter, S.Moreno-Bueno, G.Fulford, L.G.Mackay, A.Grigoriadis, A.Fenwick, K.Tamber, N.Hardisson, D.Tutt, A.Palacios, J.Buerger, H.Lord, C.J.Ashworth, A.Reis-Filho, J.S. (2009). Molecular Profiling of Grade III Invasive Ductal Breast Cancers Identifies PPM1D Amplification as a Therapeutic Target in Luminal and HER2 Tumours, MODERN PATHOLOGY, Vol.22, p.59A.

Tutt, A.Gillett, C.Pinder, S.A'Hern, R.P.Dowsett, M.Ellis, I.O.Bartlett, J.Bliss, J.M.Johnston, S.Ellis, P. (2009). Microtubule Associated Protein Tau Expression as a Predictive and Prognostic Marker in a Trial Assessing Sequential Docetaxel as Adjuvant Chemotherapy for Early Breast Cancer (TACT)., Presented at 32nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio. CANCER RESEARCH, Vol.69 (24), pp.523S-1.

Audeh, M.W.Penson, R.T.Friedlander, M.Powell, B.Bell-McGuinn, K.M.Scott, C.Weitzel, J.N.Carmichael, J.Tutt, A. (2009). Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer, JOURNAL OF CLINICAL ONCOLOGY, Vol.27 (15).

Tutt, A.Robson, M.Garber, J.E.Domchek, S.Audeh, M.W.Weitzel, J.N.Friedlander, M.Carmichael, J. (2009). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer, JOURNAL OF CLINICAL ONCOLOGY, Vol.27 (18).

Reis Filho, J.S.Turner, N.Schmitt, F.C.Tutt, A.Ashworth, A. (2006). BRCA1 gene promoter methylation in metaplastic breast carcinomas, JOURNAL OF PATHOLOGY, Vol.210, p.59.

Tutt, A.N.van Oostrom, C.Ross, G.M.van Steeg, H.Ashworth, A. (2001). Loss of BRCA2 increases in vivo somatic mutation induction by ionising radiation., BREAST CANCER RESEARCH AND TREATMENT, Vol.69 (3), p.255.

Tutt, A.Gabriel, A.Bertwistle, B.Connor, F.Paterson, H.Peacock, J.Ross, G.Ashworth, A. (2000). Absence of BRCA2 causes genomic instability, BRITISH JOURNAL OF CANCER, Vol.83, p.25.

Ashworth, A.Bertwistle, D.Conner, F.Gabriel, A.Kerr, P.Marston, N.Partridge, N.Smith, A.Swift, S.Tutt, A.Valentine, J.Warren, M.Peacock, J.Ross, G. (1999). Analysis of the breast cancer susceptibility gene BRCA2, BRITISH JOURNAL OF CANCER, Vol.80, p.4.

Ross, G.Tutt, A.Bertwhistle, D.Ashworth, A. (1998). Role of BRCA2 in DNA repair: Implications for breast carcinogenesis and therapy., BRITISH JOURNAL OF CANCER, Vol.78, p.25.

In this section

Research overview Research projects Publications